Daniel Kohlstaedt, managing director and founder of PurpleLeaf Strategy, outlines the key elements brand planning platform technology must have to help brand teams optimise their strategies.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.